[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1149721A1 - 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物 - Google Patents

基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物

Info

Publication number
HK1149721A1
HK1149721A1 HK11107642.4A HK11107642A HK1149721A1 HK 1149721 A1 HK1149721 A1 HK 1149721A1 HK 11107642 A HK11107642 A HK 11107642A HK 1149721 A1 HK1149721 A1 HK 1149721A1
Authority
HK
Hong Kong
Prior art keywords
arb
nep
superstructures
blocker
inhibitor
Prior art date
Application number
HK11107642.4A
Other languages
English (en)
Inventor
Suliman Al-Fayoumi
Jiahui Hu
Natrajan Kumaraperumal
Alan Edward Royce
Colleen Ruegger
Erika Aina Zannou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1149721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1149721A1 publication Critical patent/HK1149721A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11107642.4A 2007-11-06 2010-10-19 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物 HK1149721A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
HK1149721A1 true HK1149721A1 (zh) 2011-10-14

Family

ID=40451030

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11107642.4A HK1149721A1 (zh) 2007-11-06 2010-10-19 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物
HK10109891.9A HK1143529A1 (zh) 2007-11-06 2010-10-19 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物
HK16112495.7A HK1224195A1 (zh) 2007-11-06 2016-10-31 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的藥物組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK10109891.9A HK1143529A1 (zh) 2007-11-06 2010-10-19 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物
HK16112495.7A HK1224195A1 (zh) 2007-11-06 2016-10-31 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的藥物組合物

Country Status (34)

Country Link
US (3) US20100267786A1 (zh)
EP (4) EP4186491A1 (zh)
JP (2) JP5653218B2 (zh)
KR (2) KR101700062B1 (zh)
CN (2) CN101848700A (zh)
AR (1) AR069184A1 (zh)
AU (1) AU2008324878B2 (zh)
BR (1) BRPI0823505A2 (zh)
CA (1) CA2703598C (zh)
CL (1) CL2008003298A1 (zh)
CY (2) CY1116280T1 (zh)
DK (3) DK3067043T3 (zh)
EC (1) ECSP10010160A (zh)
ES (3) ES2587336T3 (zh)
FI (1) FI3067043T3 (zh)
GT (1) GT201000131A (zh)
HK (3) HK1149721A1 (zh)
HR (3) HRP20230178T3 (zh)
HU (2) HUE061321T2 (zh)
IL (3) IL262990B2 (zh)
JO (1) JOP20080499B1 (zh)
MA (1) MA31797B1 (zh)
MX (1) MX2010004930A (zh)
MY (1) MY153730A (zh)
NZ (1) NZ584686A (zh)
PE (2) PE20091390A1 (zh)
PL (3) PL2217205T3 (zh)
PT (3) PT2295035T (zh)
RU (1) RU2493844C3 (zh)
SG (1) SG185951A1 (zh)
SI (3) SI3067043T1 (zh)
TN (1) TN2010000200A1 (zh)
TW (1) TWI484982B (zh)
WO (1) WO2009061713A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185951A1 (en) 2007-11-06 2012-12-28 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112013004192A2 (pt) 2010-08-24 2016-05-10 Novartis Ag tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
JP6482462B2 (ja) 2012-08-24 2019-03-13 ノバルティス アーゲー 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
KR20150119107A (ko) 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
RS65037B1 (sr) 2013-08-26 2024-02-29 Novartis Ag Lečenje kardiovaskularnih oboljenja
EP3038653A1 (en) * 2013-08-26 2016-07-06 Novartis AG New use
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN105873586B (zh) 2014-12-08 2019-09-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的晶型及其制备方法
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
FI3294283T3 (fi) 2015-05-11 2023-05-24 Novartis Ag Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
EP3600255B1 (en) * 2017-03-31 2021-07-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) * 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
EP3658122B1 (en) 2017-07-28 2021-04-07 Synthon B.V. Pharmaceutical composition comprising sacubitril and valsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
WO2019246503A1 (en) 2018-06-22 2019-12-26 Ideaz, Llc Diphenyl tablets and methods of preparing the same
JP2021525791A (ja) 2018-08-23 2021-09-27 ノバルティス アーゲー 新たな心不全治療用医薬の使用
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
KR100597922B1 (ko) * 1997-11-17 2006-07-10 스미스클라인 비참 코포레이션 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU750122C (en) * 1998-06-17 2003-02-27 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
TR200805275T2 (tr) * 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
ES2309090T3 (es) 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.
DE60315795T2 (de) 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
WO2007052307A2 (en) 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
EP1951111B1 (en) 2005-11-07 2010-08-11 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
US20080261958A1 (en) 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
SG185951A1 (en) 2007-11-06 2012-12-28 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Also Published As

Publication number Publication date
HRP20230178T3 (hr) 2023-03-31
JP2011503082A (ja) 2011-01-27
EP3067043B1 (en) 2022-11-30
WO2009061713A1 (en) 2009-05-14
CA2703598A1 (en) 2009-05-14
KR101589317B1 (ko) 2016-01-28
CY1117883T1 (el) 2017-05-17
EP3067043A1 (en) 2016-09-14
HUE028866T2 (en) 2017-01-30
RU2010123027A (ru) 2011-12-20
IL262990B1 (en) 2023-06-01
TWI484982B (zh) 2015-05-21
PT3067043T (pt) 2023-03-01
KR101589317B9 (ko) 2022-11-23
IL205208A (en) 2017-01-31
ES2536514T3 (es) 2015-05-26
EP2295035A2 (en) 2011-03-16
DK3067043T3 (da) 2023-02-27
MX2010004930A (es) 2010-05-27
DK2295035T3 (en) 2016-08-29
PT2217205E (pt) 2015-06-08
JP2015038069A (ja) 2015-02-26
IL262990B2 (en) 2023-10-01
IL249922A0 (en) 2017-03-30
KR101700062B9 (ko) 2022-11-23
HRP20150459T1 (hr) 2015-07-17
EP2217205A1 (en) 2010-08-18
MY153730A (en) 2015-03-13
CN103251587A (zh) 2013-08-21
IL262990A (en) 2018-12-31
AU2008324878B2 (en) 2013-04-18
EP4186491A1 (en) 2023-05-31
CL2008003298A1 (es) 2009-06-26
CY1116280T1 (el) 2017-03-15
HK1143529A1 (zh) 2011-01-07
PL3067043T3 (pl) 2023-05-08
NZ584686A (en) 2013-03-28
AU2008324878A1 (en) 2009-05-14
KR20100085087A (ko) 2010-07-28
GT201000131A (es) 2012-04-30
PL2217205T3 (pl) 2015-07-31
IL205208A0 (en) 2010-12-30
ECSP10010160A (es) 2010-06-29
HUE061321T2 (hu) 2023-06-28
DK2217205T3 (en) 2015-05-11
PE20141072A1 (es) 2014-09-10
ES2587336T3 (es) 2016-10-24
JP5653218B2 (ja) 2015-01-14
RU2493844C2 (ru) 2013-09-27
EP2295035A3 (en) 2012-08-08
TN2010000200A1 (en) 2011-11-11
HRP20160988T1 (hr) 2016-10-07
EP2217205B1 (en) 2015-03-04
SI2295035T1 (sl) 2016-09-30
AR069184A1 (es) 2010-01-06
FI3067043T3 (fi) 2023-03-18
PT2295035T (pt) 2016-08-22
CA2703598C (en) 2016-08-09
KR101700062B1 (ko) 2017-01-26
JOP20080499B1 (ar) 2022-09-15
MA31797B1 (fr) 2010-10-01
SI2217205T1 (sl) 2015-10-30
PE20091390A1 (es) 2009-10-13
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
SG185951A1 (en) 2012-12-28
SI3067043T1 (sl) 2023-04-28
KR20150139624A (ko) 2015-12-11
EP2295035B1 (en) 2016-05-18
CN101848700A (zh) 2010-09-29
TW200936183A (en) 2009-09-01
BRPI0823505A2 (pt) 2015-06-16
HK1224195A1 (zh) 2017-08-18
ES2939163T3 (es) 2023-04-19
US20210085631A1 (en) 2021-03-25
US20100267786A1 (en) 2010-10-21
PL2295035T3 (pl) 2016-11-30

Similar Documents

Publication Publication Date Title
IL262990A (en) Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures
HUS1600025I1 (hu) Egy angiotenzin receptor antagonistát és egy NEP inhibitort tartalmazó gyógyászati kombinációk
ZA200901694B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PL2046887T3 (pl) Kompozycje poliolefinowe ulegające sieciowaniu pod wpływem światła
IL192613A (en) Cycloalkylamines and their pharmaceutical compositions
IL194734A0 (en) Pharmaceutical compositions containing opioid antagonists
DK2059246T3 (da) Terapeutiske sammensætninger omfattende en specifik endothelin-receptorantagonist og en PDE5-inhibitor
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
EP2155160A4 (en) THIXOTROPIC PHARMACEUTICAL COMPOSITIONS
AP2009004881A0 (en) Poly-TLR antagonist
ITMI20062230A1 (it) Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
GB0619891D0 (en) Pharmaceutical composition of risedronate
ZA200901001B (en) Antiretroviral solid oral composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201031